L-Form Switching in Escherichia coli as a Common β-Lactam Resistance Mechanism.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
26 10 2022
Historique:
pubmed: 15 9 2022
medline: 29 10 2022
entrez: 14 9 2022
Statut: ppublish

Résumé

Cell wall deficient bacterial L-forms are induced by exposure to cell wall-targeting antibiotics and immune effectors such as lysozyme. L-forms of different bacteria (including Escherichia coli) have been reported in human infections, but whether this is a normal adaptive strategy or simply an artifact of antibiotic treatment in certain bacterial species remains unclear. Here we show that members of a representative, diverse set of pathogenic E. coli readily proliferate as L-forms in supratherapeutic concentrations of the broad-spectrum antibiotic meropenem. We report that they are completely resistant to antibiotics targeting any penicillin-binding proteins in this state, including PBP1A/1B, PBP2, PBP3, PBP4, and PBP5/6. Importantly, we observed that reversion to the cell-walled state occurs efficiently, less than 20 h after antibiotic cessation, with few or no changes in DNA sequence. We defined for the first time a logarithmic L-form growth phase with a doubling time of 80 to 190 min, followed by a stationary phase in late cultures. We further demonstrated that L-forms are metabolically active and remain normally susceptible to antibiotics that affect DNA torsion and ribosomal function. Our findings provide insights into the biology of L-forms and help us understand the risk of β-lactam failure in persistent infections in which L-forms may be common.

Identifiants

pubmed: 36102643
doi: 10.1128/spectrum.02419-22
pmc: PMC9603335
doi:

Substances chimiques

Anti-Bacterial Agents 0
beta-Lactams 0
Escherichia coli Proteins 0
Meropenem FV9J3JU8B1
Muramidase EC 3.2.1.17
PBP5 protein, E coli 0
Penicillin-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0241922

Références

J Clin Microbiol. 2016 May;54(5):1243-50
pubmed: 26912748
J Antimicrob Chemother. 2012 Sep;67(9):2069-89
pubmed: 22618862
Philos Trans R Soc Lond B Biol Sci. 2016 Nov 5;371(1707):
pubmed: 27672147
Nat Rev Microbiol. 2007 Jan;5(1):48-56
pubmed: 17143318
Proc Biol Sci. 2018 Jun 13;285(1880):
pubmed: 29899074
FEBS J. 2022 Aug;289(16):4718-4730
pubmed: 34109739
J Vis Exp. 2020 Jun 13;(160):
pubmed: 32597873
Curr Biol. 2015 Jun 15;25(12):1613-8
pubmed: 26051891
Nat Rev Microbiol. 2016 Aug 11;14(9):549-62
pubmed: 27510862
Microbiol Spectr. 2016 Apr;4(2):
pubmed: 27227291
Sci Rep. 2018 Oct 8;8(1):14961
pubmed: 30297723
Front Microbiol. 2015 Sep 30;6:1003
pubmed: 26483762
Nature. 2009 Feb 12;457(7231):849-53
pubmed: 19212404
Nat Commun. 2019 Sep 26;10(1):4379
pubmed: 31558767
Emerg Microbes Infect. 2014 Jan;3(1):e3
pubmed: 26038493
FEMS Immunol Med Microbiol. 2012 Jul;65(2):395-8
pubmed: 22524448
Cell. 2018 Feb 22;172(5):1038-1049.e10
pubmed: 29456081
Appl Environ Microbiol. 2013 Dec;79(23):7116-21
pubmed: 24038684
Microb Ecol. 2017 Feb;73(2):368-377
pubmed: 27628741
J Bacteriol. 1985 Jan;161(1):238-42
pubmed: 3881387
Elife. 2014 Oct 30;3:
pubmed: 25358088
PLoS One. 2009 Oct 06;4(10):e7316
pubmed: 19806199
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Nat Commun. 2019 Mar 12;10(1):1177
pubmed: 30862812
Nat Microbiol. 2020 Mar;5(3):465-472
pubmed: 32066959
J Vis Exp. 2011 Jul 28;(53):
pubmed: 21841760
FEMS Microbiol Rev. 2017 May 1;41(3):219-251
pubmed: 28333307
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60
pubmed: 21859938
Open Biol. 2022 Jun;12(6):210379
pubmed: 35673854
J Bacteriol. 1987 Nov;169(11):5308-10
pubmed: 3312172
Curr Microbiol. 2009 Aug;59(2):173-80
pubmed: 19472004
Cell Res. 2013 May;23(5):728-31
pubmed: 23588382
J Bacteriol. 2012 Jul;194(14):3742-3
pubmed: 22740669
J Bacteriol. 1991 Jun;173(11):3500-6
pubmed: 2045370
J Biol Chem. 2005 Nov 18;280(46):38146-52
pubmed: 16144833
Open Forum Infect Dis. 2021 Aug 02;8(8):ofab387
pubmed: 34395716
J Biol Chem. 1988 Jul 25;263(21):10088-95
pubmed: 3292521
Annu Rev Microbiol. 1993;47:855-74
pubmed: 8257118
Cell. 2013 Feb 28;152(5):997-1007
pubmed: 23452849
Elife. 2016 Oct 21;5:
pubmed: 27767957
Clin Microbiol Infect. 2000;6 Suppl 3:34-40
pubmed: 11449647

Auteurs

Aleksandra Petrovic Fabijan (A)

Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
Sydney Medical School, The University of Sydneygrid.1013.3, Sydney, New South Wales, Australia.

David Martinez-Martin (D)

School of Biomedical Engineering, The University of Sydneygrid.1013.3, Sydney, New South Wales, Australia.
The University of Sydneygrid.1013.3 Nano Institute, The University of Sydney, Sydney, New South Wales, Australia.

Carola Venturini (C)

Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
Sydney Medical School, The University of Sydneygrid.1013.3, Sydney, New South Wales, Australia.

Katarzyna Mickiewicz (K)

Centre for Bacterial Cell Biology, Bioscience Institute, Newcastle Universitygrid.1006.7, Newcastle upon Tyne, United Kingdom.

Neftali Flores-Rodriguez (N)

Australian Centre for Microscopy and Microanalysis, University of Sydneygrid.1013.3, Sydney, New South Wales, Australia.

Jeff Errington (J)

Centre for Bacterial Cell Biology, Bioscience Institute, Newcastle Universitygrid.1006.7, Newcastle upon Tyne, United Kingdom.

Jonathan Iredell (J)

Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
Sydney Medical School, The University of Sydneygrid.1013.3, Sydney, New South Wales, Australia.
Westmead Hospital, Western Sydney Local Health District, Sydney, New South Wales, Australia.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Humans China Cerebral Hemorrhage Patient Care Bundles Length of Stay

Classifications MeSH